Mounjaro vs Wegovy: Which Weight Loss Injection Is Right for You?

If you’ve been researching weight loss injections, you’ve almost certainly landed on the mounjaro vs wegovy debate. Both are weekly GLP-1 medications that produce significant weight loss, both are administered by self-injection, and both cost roughly the same. Yet they are not the same drug, and choosing between them matters. A 2025 head-to-head trial published in the New England Journal of Medicine found tirzepatide (Mounjaro) produced 20.2% average body weight loss compared with 13.7% for semaglutide (Wegovy), a difference of roughly 13 extra pounds for a 200-pound person. That gap is worth understanding before you speak to your doctor.

This guide walks through the differences that actually matter for patients: active ingredients, approvals, effectiveness, side effects, and cost.

How Mounjaro and Wegovy work differently

Wegovy contains semaglutide, a GLP-1 receptor agonist. It mimics a gut hormone released after eating, signalling fullness to the brain and slowing how quickly the stomach empties. One mechanism, one target.

Mounjaro contains tirzepatide, which hits two targets: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP receptors are found in fat tissue, and activating them appears to improve fat breakdown and insulin sensitivity beyond what GLP-1 alone achieves. Think of it as two levers instead of one.

That dual action is probably why Mounjaro produces more weight loss on average. It is also why Mounjaro was initially developed and approved for Type 2 diabetes, where targeting two hormones gives better blood sugar control.

Both are once-weekly subcutaneous injections, delivered via pre-filled pen into the abdomen, thigh, or upper arm.

Mounjaro vs Wegovy: what each drug is approved for

This distinction catches many patients off guard. Wegovy is approved by the MHRA for weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related condition such as hypertension or prediabetes. It also carries regulatory approval for reducing cardiovascular risk in overweight adults with existing heart disease.

Mounjaro is approved for Type 2 diabetes. Weight loss is observed, substantial, and increasingly the reason doctors prescribe it, but in the UK it is prescribed off-label for weight management unless the prescriber is following evolving clinical guidance. Zepbound, the same tirzepatide molecule rebranded for obesity, is available in the United States but not yet approved in the UK under that name.

Why does this matter? Insurance and NHS coverage follows approved indications. Wegovy’s approval for weight management makes access more straightforward through weight management services. Mounjaro’s off-label status for weight loss means private prescribing is more common for that indication.

Both drugs are prescription-only medications. A clinical consultation is required before either can be supplied.

Neither is approved for use during pregnancy.

Mounjaro vs Wegovy: weight loss effectiveness compared

The 2025 NEJM trial is the most rigorous head-to-head comparison available. In 751 non-diabetic adults with obesity over 72 weeks, tirzepatide produced an average 20.2% reduction in body weight versus 13.7% for semaglutide (Source: NEJM, 2025). The tirzepatide group also showed greater reductions in waist circumference.

A few caveats worth naming. First, these are averages. Individual responses vary considerably based on adherence, diet, baseline metabolic health, and genetics. Some patients lose more on semaglutide than others lose on tirzepatide. Second, Novo Nordisk is seeking approval for a higher 2.4 mg dose of semaglutide (and a 7.2 mg dose in trials), which has shown weight loss approaching 21%, narrowing the gap. Third, the trial was not blinded and received manufacturer funding, which the British Heart Foundation’s analysis of the study noted as limitations to keep in mind.

Both plateau around 72 weeks. Both require continued use to maintain results; most patients regain significant weight within months of stopping.

For a broader look at how both sit within the wider world of injectable treatments, the weight loss treatments hub on Star Pharmacy covers the current options in detail.

Dosage schedules: what to expect

Wegovy starts at 0.25 mg weekly and increases every four weeks: 0.25 → 0.5 → 1 → 1.7 → 2.4 mg at maintenance. The titration is gradual by design, allowing the body to adjust.

Mounjaro starts at 2.5 mg weekly and increases every four weeks: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg at maximum. Higher maximum doses reflect the different pharmacology and the dual-agonist mechanism.

Both pens require refrigeration until first use. Wegovy pens can remain at room temperature for up to 28 days; Mounjaro pens for 21 days.

Dose escalation can be paused if side effects become difficult to manage. Some patients stabilise at lower than maximum doses and still achieve meaningful weight loss. If you want a detailed breakdown of Mounjaro’s specific escalation steps, the Mounjaro dosage guide on Star Pharmacy walks through each stage clearly.

BMI eligibility applies to both: a BMI of 30 or above, or 27 and above with a relevant comorbidity, is the standard clinical threshold for prescribing.

Side effects: similar profiles, subtle differences

The side effect profiles are comparable. Nausea, diarrhoea, constipation, and vomiting are the most common complaints for both, occurring predominantly during dose escalation and typically easing as the body adapts. Around 77–79% of users report at least one gastrointestinal symptom at some point.

Discontinuation rates due to side effects were 6–8% for tirzepatide and 7–10% for semaglutide in clinical trials. There is some suggestion that tirzepatide’s GIP component may provide a mild antiemetic effect, reducing nausea slightly, though the clinical significance of this difference is debated.

Both carry a black-box warning for thyroid C-cell tumours based on animal studies. This has not been confirmed in humans, but both drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Other uncommon but serious risks include pancreatitis, gallbladder disease, and acute kidney injury.

Practical ways to reduce nausea: eat smaller, lower-fat meals; stay well hydrated; take your injection on an evening so any initial nausea occurs overnight; avoid lying down immediately after eating.

Cost and access in the UK

Private prescriptions for both run roughly £150–£300 per month depending on dose and provider, though prices vary. Manufacturer savings programmes and specific pharmacy pricing can affect the figure.

NHS access to Wegovy expanded following NICE guidance in 2023, primarily through specialist weight management services, though availability is not yet universal. Mounjaro for weight management remains largely a private prescription in the UK for patients without Type 2 diabetes.

Long-term cost is a real consideration. Weight regain after stopping means most patients need to continue indefinitely or accept some regain. Factor that into any budget calculation before starting.

Which injection suits you better?

There is no universal answer, but a few pointers help narrow it down.

Consider Wegovy if cardiovascular risk reduction matters to you specifically, if you have an established heart condition, or if NHS access through a weight management service is possible for your situation.

Consider Mounjaro if maximising weight loss is the priority and you are comfortable with private prescribing, or if you have Type 2 diabetes and want dual benefit for both glucose control and weight.

If you are weighing up Mounjaro against other injectable options beyond Wegovy, the Ozempic vs Mounjaro comparison on Star Pharmacy covers that question in depth.

Switching between medications is possible. Most clinical guidance suggests a seven-day washout period and restarting at the lowest dose of the new drug, even if you were at a higher dose on the previous one. Do not switch without guidance from your prescriber.

Conclusion

The mounjaro vs wegovy decision comes down to a handful of personal factors: how much weight loss you are hoping to achieve, whether cardiovascular protection is a clinical priority, your eligibility for NHS prescribing, and what you can sustain financially long term. Mounjaro’s superior average efficacy is real and meaningful. Wegovy’s approved cardiovascular benefit and more established NHS access route are also real advantages. Neither drug replaces diet and exercise; both work best alongside genuine lifestyle changes.

If you are ready to explore your options, you can order Wegovy or Mounjaro through Star Pharmacy’s weight loss injection service following a clinical consultation with a registered prescriber.

FAQs

Is Mounjaro stronger than Wegovy for weight loss?

In head-to-head clinical trials, tirzepatide (Mounjaro) produced greater average weight loss than semaglutide (Wegovy): 20.2% versus 13.7% over 72 weeks in a 2025 NEJM study. However, individual responses vary, and “stronger” does not mean better for every patient.

Can I switch from Wegovy to Mounjaro?

Yes, switching is possible. Most guidance recommends a seven-day break between stopping one medication and starting the other, then restarting at the lowest dose of the new drug. Always do this under medical supervision, not independently.

Are the side effects worse on Mounjaro than Wegovy?

The side effect profiles are broadly similar. Nausea, diarrhoea, and constipation are common with both during dose escalation. Discontinuation rates due to side effects are comparable across both drugs in clinical trial data.

Which drug is available on the NHS?

Wegovy received NICE approval for weight management and is available through some NHS specialist weight management services. Mounjaro is NHS-approved for Type 2 diabetes; for weight loss in patients without diabetes, it is typically accessed privately in the UK at present.

Do I need a prescription for either drug?

Yes. Both Mounjaro and Wegovy are prescription-only medications. A clinical consultation with a qualified prescriber is required before either can be dispensed.